Wednesday, 25 Apr 2018

You are here

ACR Projects Significant Manpower Shortages for 2030

Arthritis & Rheumatology has published the results of the 2015 Workforce Study of Rheumatology Specialists, and estimates a current shortage (demand > supply) of 700 (12.9%) full-time rheumatologists and that this deficit will worsen (102%) to 4133 FTE by 2030.

Using primary and secondary data sources, the committee estimated the baseline adult rheumatology workforce and determined supply vs demand projections through 2030.

As of 2015, the  adult workforce (physicians, nurse practitioners, and physician assistants) was estimated to be 6,013 providers (5,415 clinical FTE). At baseline, the estimated demand exceeded the supply of clinical FTE by 700 (12.9%).

Previous projections for a manpower shortfall lead to a 4.6% increase in adult fellowship programs (108 to 113) and a 17.6% increase in fellow-ship positions, from 398 to 468.  Nevertheless, the increase in training is insufficient to close the gap between supply and future demand.

Other key points from this article:

  • There is a geographic maldistribution of adult rheumatologists across the US that will worsen over the next 15 years.
  • These deficits are in part related to baby‐boomer retirements, a millennial predominance, and an increase of female and part‐time providers, in parallel with an increased demand for adult rheumatology care due to an increasing and aging US population.
  • Effective strategies to recruit fellows, nurse practitioners, and physician assistants to support the adult rheumatology workforce will be necessary to address the anticipated workforce gap.
  • Processes to retain rheumatology providers in the workforce and to facilitate access to quality care must be explored.

ACR/ARHP workforce projects a significant adult rheumatology workforce shortage over the next 15 years; this is in parallel with the projections for a national physician shortage and shortages in other sub-specialties.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The RheumNow Week in Review – Vitamin D Snark Report (4.20.18)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.  A second life for Syk kinase, Vitamin D talk, VTE, regulatory hearings and the Lupus clinic edge.

RheumNow Week in Review - Do you Dig Shingrix? (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlights includes manpower shortfalls, comorbidities in AA Lupus, certolizumab pregnancy safety, which Shingles vaccine is best and the power of combination biologics in severe refractory  SLE.

"Breakthrough" Drug Designation by the FDA

The current issue of the NEJM reviews the Food and Drug Administration (FDA) “breakthrough therapy” designation that was introduced in 2012 to expedite testing and approval of medications that were intended to treat serious or life-threatening conditions.  This status is granted when preliminary evidence with a new drug suggests substantial benefits over existing therapies for these unfortunate conditions.

RheumNow Week in Review -The Temporal Artery Biopsy Letdown (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. News on the cost of RA care, infections on planes, CV events and Sacroiliitis in IBD, NXP-2 antibodies and calcinosis and rituximab in myositis ILD patients.

The RheumNow Week in Review -30 March 2018

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. News on drug regulatory decisions, fenofibrate and gout, Still's disease, TB and infection rates, SpA and hidradenitis suppurativa, and predicting methotrexate non-responders.